Prognostic value of right ventricular involvement in hypertrophic cardiomyopathy: A systematic review and meta-analysis.

Fractional area change Hypertrophic cardiomyopathy Prognosis Right ventricle Systolic dysfunction meta-analysis

Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
24 Jul 2024
Historique:
received: 09 01 2024
revised: 07 04 2024
accepted: 23 07 2024
medline: 27 7 2024
pubmed: 27 7 2024
entrez: 26 7 2024
Statut: aheadofprint

Résumé

Right ventricular (RV) involvement has been reported in one out of three patients with hypertrophic cardiomyopathy (HCM), however its prognostic significance remains unknown. We aimed to assess the prognostic value of RV involvement in patients with HCM through a systematic review and meta-analysis. A literature search was performed on PubMed, ClinicalTrials.gov and Cochrane Library databases from inception through November 15, 2023. Original articles enrolling HCM patients >18 years and evaluating the association of RV parameters routinely assessed in clinical practice through trans-thoracic echocardiography or cardiac magnetic resonance (i.e., RV hypertrophy, volumes, systolic function, and late‑gadolinium-enhancement) and the risk of a pre-defined composite endpoint including i) all-cause-death; ii) cardiac-death; iii) heart-transplantation; iv) heart-failure-related-hospitalization; v) atrial-fibrillation; vi) ventricular-tachycardia; vii) stroke were retrieved. We pooled the effect of RV imaging variables on the combined clinical endpoint in terms of hazard ratio (HR) with 95% confidence interval (CI). The meta-analysis included 12 articles and 4634 patients. The pooled analysis demonstrated that the presence of RV systolic dysfunction conveyed an increased risk of adverse outcomes (HR 2.46; 95% CI 1.80-3.35; P < 0.001), whereas other RV imaging parameters were not significantly associated with patients' prognosis, except for RV-fractional area change analyzed as a continuous variable (HR 0.96 per % increase; 95% CI 0.93-0.995; P = 0.025). Our results pinpoint a prognostic role of RV dysfunction, independent of LV involvement, in patients with HCM, and future longitudinal studies, including multi-parametric RV assessment, are encouraged to provide clinically relevant data to refine risk stratification in patients with HCM.

Sections du résumé

BACKGROUND BACKGROUND
Right ventricular (RV) involvement has been reported in one out of three patients with hypertrophic cardiomyopathy (HCM), however its prognostic significance remains unknown. We aimed to assess the prognostic value of RV involvement in patients with HCM through a systematic review and meta-analysis.
METHODS METHODS
A literature search was performed on PubMed, ClinicalTrials.gov and Cochrane Library databases from inception through November 15, 2023. Original articles enrolling HCM patients >18 years and evaluating the association of RV parameters routinely assessed in clinical practice through trans-thoracic echocardiography or cardiac magnetic resonance (i.e., RV hypertrophy, volumes, systolic function, and late‑gadolinium-enhancement) and the risk of a pre-defined composite endpoint including i) all-cause-death; ii) cardiac-death; iii) heart-transplantation; iv) heart-failure-related-hospitalization; v) atrial-fibrillation; vi) ventricular-tachycardia; vii) stroke were retrieved. We pooled the effect of RV imaging variables on the combined clinical endpoint in terms of hazard ratio (HR) with 95% confidence interval (CI).
RESULTS RESULTS
The meta-analysis included 12 articles and 4634 patients. The pooled analysis demonstrated that the presence of RV systolic dysfunction conveyed an increased risk of adverse outcomes (HR 2.46; 95% CI 1.80-3.35; P < 0.001), whereas other RV imaging parameters were not significantly associated with patients' prognosis, except for RV-fractional area change analyzed as a continuous variable (HR 0.96 per % increase; 95% CI 0.93-0.995; P = 0.025).
CONCLUSIONS CONCLUSIONS
Our results pinpoint a prognostic role of RV dysfunction, independent of LV involvement, in patients with HCM, and future longitudinal studies, including multi-parametric RV assessment, are encouraged to provide clinically relevant data to refine risk stratification in patients with HCM.

Identifiants

pubmed: 39059475
pii: S0167-5273(24)01012-X
doi: 10.1016/j.ijcard.2024.132390
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

132390

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Stefano Figliozzi (S)

IRCCS Humanitas Research Hospital, Via Alessandro Manzoni 56, Rozzano, 20089 Milan, Italy. Electronic address: stefano.figliozzi@humanitas.it.

Pier-Giorgio Masci (PG)

School of Biomedical Engineering and Imaging Sciences-Faculty of Life Sciences and Medicine, King's College London, Westminster Bridge Rd, London SE1 7EH, England, United Kingdom.

Lorenzo Monti (L)

IRCCS Humanitas Research Hospital, Via Alessandro Manzoni 56, Rozzano, 20089 Milan, Italy; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy.

Kamil Stankowski (K)

IRCCS Humanitas Research Hospital, Via Alessandro Manzoni 56, Rozzano, 20089 Milan, Italy; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy.

Lara Tondi (L)

Multimodality Cardiac Imaging Section, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy; Department of Radiology, IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.

Evmorfia Aivalioti (E)

Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece.

Georgios Mavraganis (G)

Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece.

Marco Francone (M)

IRCCS Humanitas Research Hospital, Via Alessandro Manzoni 56, Rozzano, 20089 Milan, Italy; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy.

Gianluigi Condorelli (G)

IRCCS Humanitas Research Hospital, Via Alessandro Manzoni 56, Rozzano, 20089 Milan, Italy; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy.

Iacopo Olivotto (I)

Cardiomyopathy Unit, Careggi University Hospital, Largo Brambilla 3, 50134 Florence, Italy.

Georgios Georgiopoulos (G)

Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece.

Classifications MeSH